| 查看: 164 | 回复: 1 | |||
| 当前主题已经存档。 | |||
zhantian3529铁杆木虫 (正式写手)
|
[交流]
【转帖】Drug R&D Heats Up In Beijing
|
||
|
Pharmaceutical Product Development, a U.S.-based contract drug R&D firm, has agreed to acquire BioDuro, a drug discovery services supplier that mostly operates out of labs in Beijing. Separately, Merck Serono says it will spend $225 million to build a corporate research lab, also in Beijing. Together, the deals demonstrate the drug industry’s acceptance of Beijing as a worthy R&D hub. Employing about 660 people in chemistry-oriented research facilities in the Chinese capital, BioDuro was one of the first companies in either China or India to offer integrated drug discovery services from target validation all the way to the supply of clinical candidates. The four-year-old company was formed in San Diego by two California entrepreneurs, Masood Tayebi and John Oyler. In an interview last year, Oyler said he had no intention to quickly sell BioDuro at a profit, as he had done with other companies (C&EN, Feb. 4, 2008, page 11). “I’d like to be involved in the development of a new technology that could cure a major disease,” he said. “That would be spectacular.” Oyler did not respond to C&EN’s request for comments about the change of heart. BioDuro’s “management team will remain,” a PPD spokeswoman tells C&EN. PPD is buying BioDuro, she says, to “expand our drug discovery segment and better position PPD in China.” Employing 10,500 people in 38 countries, PPD is best known for its clinical and postapproval research services. Meanwhile, Merck Serono says its new Beijing lab will employ as many as 200 scientists within four years. The facility, which Merck says will be one of its key R&D hubs worldwide, will mostly manage clinical trials. Up to now, Shanghai has been more popular than Beijing for foreign companies establishing R&D operations in China. The two cities are quite different, says Han Yongxin, the Beijing-based head of China operations at the drug discovery services firm Chemizon. “Shanghai is a very well developed services- and business-oriented city. You can also do business in Beijing,” Han says, but the city’s environment is best for research. He adds that scientists in Beijing tend to stay in their jobs longer “because they’re really interested in conducting research.”—Jean-François Tremblay Chemical & Engineering News ISSN 0009-2347 Copyright © 2009 American Chemical Society 本帖关键词：drug worthy acceptance mostly supplier http://pubs.acs.org/cen/news/87/i48/8748notw6.html |
回复此楼» 猜你喜欢
澳门理工大学人工智能药物发现中心招收2025级博士研究生（申请-考核制）
已经有20人回复
-
招10开头学硕，肿瘤/药物信息学方向，国家重点实验室（北京）
已经有4人回复
-
药理学论文润色/翻译怎么收费?
已经有195人回复
-
求26届aidd博导推荐
已经有4人回复
-
2026申博推荐
已经有1人回复
-
一篇扩散模型的Nature Machine Intelligence论文和Elsevier上的深度学习药物书籍
已经有1人回复
-
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究
已经有25人回复
zhantian3529
铁杆木虫 (正式写手)
- 应助: 0 (幼儿园)
- 金币: 7675.6
- 帖子: 958
- 在线: 126.9小时
- 虫号: 703421
- 注册: 2009-02-18
- 性别: GG
- 专业: 药物化学
|
In an interview last year, Oyler said he had no intention to quickly sell BioDuro at a profit, as he had done with other companies (C&EN, Feb. 4, 2008, page 11). “I’d like to be involved in the development of a new technology that could cure a major disease,” he said. “That would be spectacular.” Oyler did not respond to C&EN’s request for comments about the change of heart. John Oyler,这个专门办公司然后再卖了的投资者 |
2楼2009-12-03 16:47:54